Subcutaneous insulin is associated with drastic decrease of blood glucose levels, whereas the oral administration of recombinant human insulin loaded with functionalized liposomes provided a more sustained hypoglycemia with less side effects. The gene discussed is INS; the disease is Hypoglycemia.